{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [{"AbstractText": ["Les prot\u00e9ines d\u2019int\u00e9r\u00eat pharmaceutique ont commenc\u00e9 \u00e0 \u00eatre utilis\u00e9es au cours des ann\u00e9es 1920 avec l\u2019insuline extraite des pancr\u00e9as de porcs. Au d\u00e9but des ann\u00e9es 1980, l\u2019insuline humaine a commenc\u00e9 \u00e0 \u00eatre pr\u00e9par\u00e9e \u00e0 partir de bact\u00e9ries recombinantes et d\u00e9sormais, tous les diab\u00e9tiques utilisent cette hormone. Plusieurs autres prot\u00e9ines et notamment l\u2019hormone de croissance humaine, ont \u00e9t\u00e9 pr\u00e9par\u00e9es \u00e0 partir de bact\u00e9ries recombinantes. Ces premiers succ\u00e8s ont rapidement montr\u00e9 la limite des bact\u00e9ries qui sont incapables de synth\u00e9tiser des prot\u00e9ines ayant une structure complexe comme les anticorps ou les facteurs de coagulation sanguine. En effet, pour \u00eatre stables et actives in vivo, ces prot\u00e9ines doivent subir de multiples modifications post-traductionnelles. Les principales modifications sont le repliement, le clivage, l\u2019association des sous-unit\u00e9s, la \u03b3-carboxylation et la glycosylation. Elles ne se produisent compl\u00e8tement que dans des cellules de mammif\u00e8res cultiv\u00e9es dans des fermenteurs \u00e0 l\u2019\u00e9chelle industrielle ou appartenant \u00e0 des animaux transg\u00e9niques. Plusieurs esp\u00e8ces d\u2019animaux transg\u00e9niques peuvent produire des prot\u00e9ines recombinantes mais actuellement deux syst\u00e8mes ont commenc\u00e9 \u00e0 \u00eatre exploit\u00e9s. Le premier est le lait des animaux de ferme transg\u00e9niques qui sont \u00e9tudi\u00e9s depuis 20 ans. Ce syst\u00e8me a permis \u00e0 une prot\u00e9ine, l\u2019antithrombine III humaine, de recevoir l\u2019autorisation de mise sur le march\u00e9 par l\u2019EMEA (European Agency for the Evaluation of Medicinal Products) en 2006. Le second syst\u00e8me est le blanc d\u2019\u0153uf de poulets transg\u00e9niques qui est devenu r\u00e9cemment plus attractif apr\u00e8s que les m\u00e9thodes de pr\u00e9paration d\u2019oiseaux transg\u00e9niques aient \u00e9t\u00e9 am\u00e9lior\u00e9es. Deux anticorps monoclonaux et de l\u2019interf\u00e9ron-\u03b21a humain ont \u00e9t\u00e9 obtenus dans le blanc d\u2019\u0153uf de poulets. Une grande vari\u00e9t\u00e9 de prot\u00e9ines recombinantes a \u00e9t\u00e9 pr\u00e9par\u00e9e \u00e0 titre exp\u00e9rimental avec ces deux syst\u00e8mes et quelques autres. Ces prot\u00e9ines comprennent des anticorps monoclonaux, des vaccins, des facteurs sanguins, des hormones, des facteurs de croissance, des cytokines, des enzymes, des prot\u00e9ines du lait, du collag\u00e8ne, du fribrinog\u00e8ne et d\u2019autres encore. Bien que ces outils n\u2019aient pas \u00e9t\u00e9 optimis\u00e9s et soient encore en cours d\u2019am\u00e9lioration, une nouvelle \u00e8re dans la production de prot\u00e9ines recombinantes pharmaceutiques a commenc\u00e9 en 1987 et est devenue une r\u00e9alit\u00e9 en 2006. Dans cette revue, l\u2019efficacit\u00e9 des diff\u00e9rents syst\u00e8mes animaux capables de produire des prot\u00e9ines pharmaceutiques sont d\u00e9crits et compar\u00e9s aux autres incluant les plantes et les microorganismes."]}], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "18243312", "DateCompleted": {"Year": "2009", "Month": "04", "Day": "14"}, "DateRevised": {"Year": "2024", "Month": "01", "Day": "04"}, "Article": {"ArticleDate": [{"Year": "2008", "Month": "02", "Day": "19"}], "Language": ["eng"], "ELocationID": ["10.1016/j.cimid.2007.11.005"], "Journal": {"ISSN": "1878-1667", "JournalIssue": {"Volume": "32", "Issue": "2", "PubDate": {"Year": "2009", "Month": "Mar"}}, "Title": "Comparative immunology, microbiology and infectious diseases", "ISOAbbreviation": "Comp Immunol Microbiol Infect Dis"}, "ArticleTitle": "Production of pharmaceutical proteins by transgenic animals.", "Pagination": {"StartPage": "107", "EndPage": "121", "MedlinePgn": "107-21"}, "Abstract": {"AbstractText": ["Proteins started being used as pharmaceuticals in the 1920s with insulin extracted from pig pancreas. In the early 1980s, human insulin was prepared in recombinant bacteria and it is now used by all patients suffering from diabetes. Several other proteins and particularly human growth hormone are also prepared from bacteria. This success was limited by the fact that bacteria cannot synthesize complex proteins such as monoclonal antibodies or coagulation blood factors which must be matured by post-translational modifications to be active or stable in vivo. These modifications include mainly folding, cleavage, subunit association, gamma-carboxylation and glycosylation. They can be fully achieved only in mammalian cells which can be cultured in fermentors at an industrial scale or used in living animals. Several transgenic animal species can produce recombinant proteins but presently two systems started being implemented. The first is milk from farm transgenic mammals which has been studied for 20 years and which allowed a protein, human antithrombin III, to receive the agreement from EMEA (European Agency for the Evaluation of Medicinal Products) to be put on the market in 2006. The second system is chicken egg white which recently became more attractive after essential improvement of the methods used to generate transgenic birds. Two monoclonal antibodies and human interferon-beta 1a could be recovered from chicken egg white. A broad variety of recombinant proteins were produced experimentally by these systems and a few others. This includes monoclonal antibodies, vaccines, blood factors, hormones, growth factors, cytokines, enzymes, milk proteins, collagen, fibrinogen and others. Although these tools have not yet been optimized and are still being improved, a new era in the production of recombinant pharmaceutical proteins was initiated in 1987 and became a reality in 2006. In the present review, the efficiency of the different animal systems to produce pharmaceutical proteins are described and compared to others including plants and micro-organisms."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Biologie du D\u00e9veloppement et Reproduction, Institut National de la Recherche Agronomique, 78350 Jouy en Josas, France. louis.houdebine@jouy.inra.fr"}], "Identifier": [], "LastName": "Houdebine", "ForeName": "Louis-Marie", "Initials": "LM"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Comp Immunol Microbiol Infect Dis", "NlmUniqueID": "7808924", "ISSNLinking": "0147-9571"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Biological Products"}, {"RegistryNumber": "0", "NameOfSubstance": "Pharmaceutical Preparations"}, {"RegistryNumber": "0", "NameOfSubstance": "Recombinant Proteins"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["genetics"], "DescriptorName": "Animals, Genetically Modified"}, {"QualifierName": ["biosynthesis", "genetics"], "DescriptorName": "Biological Products"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["metabolism"], "DescriptorName": "Pharmaceutical Preparations"}, {"QualifierName": ["trends"], "DescriptorName": "Protein Engineering"}, {"QualifierName": ["biosynthesis", "genetics"], "DescriptorName": "Recombinant Proteins"}, {"QualifierName": ["genetics"], "DescriptorName": "Transgenes"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Hamilton S.R., Bobrowicz P., Bobrowicz B., Davidson R.C., Li H., Mitchell T. Production of complex human glycoproteins in yeast. Science. 2003;301:1244\u20131246.", "ArticleIdList": ["12947202"]}, {"Citation": "Ma S., Jevnikar A.M. Transgenic rice for allergy immunotherapy. Proc Natl Acad Sci USA. 2005;102:17255\u201317256.", "ArticleIdList": ["PMC1297701", "16301530"]}, {"Citation": "Gomord V., Chamberlain P., Jefferis R., Faye L. Biopharmaceutical production in plants: problems, solutions and opportunities. Trends Biotechnol. 2005;23:559\u2013565.", "ArticleIdList": ["16168504"]}, {"Citation": "Kirk D.D., McIntosh K., Walmsley A.M., Peterson R.K. Risk analysis for plant-made vaccines. Transgenic Res. 2005;14:449\u2013462.", "ArticleIdList": ["PMC7089354", "16201411"]}, {"Citation": "Abranches R., Marcel S., Arcalis E., Altmann F., Fevereiro P., Stoger E. Plants as bioreactors: a comparative study suggests that Medicago truncatula is a promising production system. J Biotechnol. 2005;120:121\u2013134.", "ArticleIdList": ["16026877"]}, {"Citation": "Leon-Banares R., Gonzalez-Ballester D., Galvan A., Fernandez E. Transgenic microalgae as green cell-factories. Trends Biotechnol. 2004;22:45\u201352.", "ArticleIdList": ["14690622"]}, {"Citation": "Hellwig S., Drossard J., Twyman R.M., Fischer R. Plant cell cultures for the production of recombinant proteins. Nat Biotechnol. 2004;22:1415\u20131422.", "ArticleIdList": ["15529167"]}, {"Citation": "Giritch A., Marillonnet S., Engler C., van Eldik G., Botterman J., Klimyuk V. Rapid high-yield expression of full-size IgG antibodies in plants coinfected with non competing viral vectors. Proc Natl Acad Sci USA. 2006;103:14701\u201314706.", "ArticleIdList": ["PMC1566189", "16973752"]}, {"Citation": "Houdebine L.M. Transgenic animal bioreactors. Transgenic Res. 2000;9:305\u2013312.", "ArticleIdList": ["PMC7089244", "11131009"]}, {"Citation": "Houdebine L.M. Antibody manufacture in transgenic animals and comparisons with other systems. Curr Opin Biotechnol. 2002;13:625\u2013629.", "ArticleIdList": ["PMC7134875", "12482525"]}, {"Citation": "Houdebine L.M. The methods to generate transgenic animals and to control transgene expression. J Biotechnol. 2002;98:145\u2013160.", "ArticleIdList": ["12141984"]}, {"Citation": "Zhu L., van de Lavoir M.C., Albanese J., Beenhouwer D.O., Cardarelli P.M., Cuison S. Production of human monoclonal antibody in eggs of chimeric chickens. Nat Biotechnol. 2005;23:1159\u20131169.", "ArticleIdList": ["16127450"]}, {"Citation": "van de Lavoir M.C., Diamond J.H., Leighton P.A., Mather-Love C., Heyer B.S., Bradshaw R. Germline transmission of genetically modified primordial germ cells. Nature. 2006;441:766\u2013769.", "ArticleIdList": ["16760981"]}, {"Citation": "Lillico S.G., Sherman A., McGrew M.J., Robertson C.D., Smith J., Haslam C. Oviduct-specific expression of two therapeutic proteins in transgenic hens. Proc Natl Acad Sci USA. 2007;104:1771\u20131776.", "ArticleIdList": ["PMC1783527", "17259305"]}, {"Citation": "Dyck M.K., Lacroix D., Pothier F., Sirard M.A. Making recombinant proteins in animals\u2014different systems, different applications. Trends Biotechnol. 2003;21:394\u2013399.", "ArticleIdList": ["12948672"]}, {"Citation": "Royer C., Jalabert A., Da Rocha M., Grenier A.M., Mauchamp B., Couble P. Biosynthesis and cocoon-export of a recombinant globular protein in transgenic silkworms. Transgenic Res. 2005;14:463\u2013472.", "ArticleIdList": ["16201412"]}, {"Citation": "Markaki M., Drabek D., Livadaras I., Craig R.K. Stable expression of human Growth Hormone over 50 generations in transgenic insect larvae. Transgenic Res. 2007;16:99\u2013107.", "ArticleIdList": ["17103025"]}, {"Citation": "Pfeifer A. Lentiviral transgenesis\u2014a versatile tool for basic research and gene therapy. Curr Gene Ther. 2006;6:535\u2013542.", "ArticleIdList": ["16918338"]}, {"Citation": "Houdebine L.M. Use of transgenic animals to improve human health and animal production. Reprod Domest Anim. 2005:40269\u201340281.", "ArticleIdList": ["PMC7190005", "16008757"]}, {"Citation": "Houdebine L.M. Transgenic animal models and target validation. Methods Mol Biol. 2006;360:163\u2013202.", "ArticleIdList": ["17172731"]}, {"Citation": "Soler E., Thepot D., Rival-Gervier S., Jolivet G., Houdebine L. Preparation of recombinant proteins in milk to improve human and animal health. Reprod Nutr Dev. 2006;46:579\u2013588.", "ArticleIdList": ["17107647"]}, {"Citation": "Morozumi K., Shikano T., Miyazaki S., Yanagimachi R. Simultaneous removal of sperm plasma membrane and acrosome before intracytoplasmic sperm injection improves oocyte activation/embryonic development. Proc Natl Acad Sci USA. 2006;103:17585\u201317586.", "ArticleIdList": ["PMC1693803", "17090673"]}, {"Citation": "Yong H.Y., Hao Y., Lai L., Li R., Murphy C.N., Rieke A. Production of a transgenic piglet by a sperm injection technique in which no chemical or physical treatments were used for oocytes or sperm. Mol Reprod Dev. 2006;73:595\u2013599.", "ArticleIdList": ["16489622"]}, {"Citation": "Rival-Gervier S., Viglietta C., Maeder C., Attal J., Houdebine L.M. Position-independent and tissue-specific expression of porcine whey acidic protein gene from a bacterial artificial chromosome in transgenic mice. Mol Reprod Dev. 2002:63161\u201363167.", "ArticleIdList": ["12203825"]}, {"Citation": "Giraldo P., Rival-Gervier S., Houdebine L.M., Montoliu L. The potential benefits of insulators heterologous contructs in transgenic animals. Transgenic Res. 2003;12:751\u2013755.", "ArticleIdList": ["14713206"]}, {"Citation": "Giersing B., Dubovsky F. Malaria vaccine initiative. Bioforum Europe. 2006;34"}, {"Citation": "Stowers A.W., Chen L.H., Zhang Y., Kennedy M.C., Zou L., Lambert L. A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proc Natl Acad Sci USA. 2002;99:339\u2013344.", "ArticleIdList": ["PMC117562", "11752405"]}, {"Citation": "Soler E., Le Saux A., Guinut F., Passet B., Cohen R., Merle C. Production of two vaccinating recombinant rotavirus proteins in the milk of transgenic rabbits. Transgenic Res. 2005;14:833\u2013844.", "ArticleIdList": ["16315090"]}, {"Citation": "Edmunds T., Van Patten S.M., Pollock J., Hanson E., Bernasconi R., Higgins E. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood. 1998;91:4561\u20134571.", "ArticleIdList": ["9616152"]}, {"Citation": "Koles K., van Berkel P.H., Pieper F.R., Nuijens J.H., Mannesse M.L., Vliegenthart J.F. N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology. 2004;14:51\u201364.", "ArticleIdList": ["14514717"]}, {"Citation": "Weikert S., Papac D., Briggs J., Cowfer D., Tom S., Gawlitzek M. Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nat Biotechnol. 1999;17:1116\u20131121.", "ArticleIdList": ["10545921"]}, {"Citation": "Umana P., Jean-Mairet J., Moudry R., Amstutz H., Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol. 1999;17:176\u2013180.", "ArticleIdList": ["10052355"]}, {"Citation": "Jefferies R. A sugar switch for anti-inflammatory antibodies. Nat Biotechnol. 2006;24:1230\u20131231.", "ArticleIdList": ["17033662"]}, {"Citation": "Lubon H. Transgenic animal bioreactors in biotechnology and production of blood proteins. Biotechnol Annu Rev. 1998;4:1\u201354.", "ArticleIdList": ["9890137"]}, {"Citation": "Drews R., Paleyanda R.K., Lee T.K., Chang R.R., Rehemtulla A., Kaufman R.J. Proteolytic maturation of protein C upon engineering the mouse mammary gland to express furin. Proc Natl Acad Sci USA. 1995;92:10462\u201310466.", "ArticleIdList": ["PMC40631", "7479820"]}, {"Citation": "Toledo J.R., Sanchez O., Segui R.M., Garcia G., Montanez M., Zamora P.A. High expression level of recombinant human erythropoietin in the milk of non-transgenic goats. J Biotechnol. 2006;123:225\u2013235.", "ArticleIdList": ["16338016"]}, {"Citation": "DiTullio P., Cheng S.H., Marchall J., Gregory R.J., Ebert K.M., Meade H.M. Production of cystic fibrosis transmembrane conductance regulator in the milk of transgenic mice. Biotechnology. 1992;10:74\u201377.", "ArticleIdList": ["1375475"]}, {"Citation": "Bodrogi L., Brands R., Raaben W., Seinen W., Baranyi M., Fiechter D. High level expression of tissue-nonspecific alkaline phosphatase in the milk of transgenic rabbits. Transgenic Res. 2006;15:627\u2013636.", "ArticleIdList": ["16826424"]}, {"Citation": "Richt J.A., Kasinathan P., Hamir A.N., Castilla J., Sathiyaseelan T., Vargas F. Production of cattle lacking prion protein. Nat Biotechnol. 2007;25:132\u2013138.", "ArticleIdList": ["PMC2813193", "17195841"]}, {"Citation": "Pettite J.N., Mozdziak P.E. The incredible, edible, and therapeutic egg. Proc Natl Acad Sci USA. 2007;104:1739\u20131740.", "ArticleIdList": ["PMC1794276", "17272493"]}, {"Citation": "Massoud M., Attal J., Thepot D., Pointu H., Stinnakre M.G., Theron M.C. The deleterious effects of human erythropoietin gene driven by the rabbit whey acidic protein gene promoter in transgenic rabbits. Reprod Nutr Dev. 1996;36:555\u2013563.", "ArticleIdList": ["8987107"]}, {"Citation": "Soler E., Parez N., Passet B., Dubuquoy C., Riffault S., Pillot M. Recombinant rotavirus inner core proteins produced in the milk of transgenic rabbits confer a high level of protection after intrarectal delivery. Vaccine. 2007;25:6373\u20136380.", "ArticleIdList": ["17629366"]}]}], "History": [{"Year": "2007", "Month": "11", "Day": "10"}, {"Year": "2008", "Month": "2", "Day": "5", "Hour": "9", "Minute": "0"}, {"Year": "2009", "Month": "4", "Day": "15", "Hour": "9", "Minute": "0"}, {"Year": "2008", "Month": "2", "Day": "5", "Hour": "9", "Minute": "0"}, {"Year": "2008", "Month": "2", "Day": "19"}], "PublicationStatus": "ppublish", "ArticleIdList": ["18243312", "PMC7112688", "10.1016/j.cimid.2007.11.005", "S0147-9571(07)00130-0"]}}], "PubmedBookArticle": []}